Table 3.
Severe toxicities according to UGT1A1*6 genotyping
| Study | No of patients | Regimens | Irinotecan dose | Neutropenia G3–4 (%)
|
Diarrhea G3–4 (%)
|
Efficacy | ||
|---|---|---|---|---|---|---|---|---|
| Odds ratio (95% CI)
|
Odds ratio (95% CI)
|
Odds ratio (95% CI)
|
Odds ratio (95% CI)
|
|||||
| *6/*6 vs *1/*1 | *1/*6 vs *1/*1 | *6/*6 vs *1/*1 | *1/*6 vs *1/*1 | |||||
| Jada et al40 | 45 | IRI | 375/3w | – | – | 7.75 (0.40–149.70) | 1.11 (0.11–11.49) | |
| Sai et al41 | 49 | IRI | 60/1w, 100, 125, 150/2w | 28.00 (0.92–851.54) | 8.00 (0.82–78.47) | – | – | |
| Takano et al42 | 30 | IRI-cisplatin | 60/1w | – | 11.20 (1.73–72.30) | – | 16.00 (1.45–176.45) | – |
| Seo et al43 | 39 | FOLFIRI | 150/2w | – | 0.97 (0.24–3.90) | – | 0.56 (0.10–3.08) | RR, OS, no difference (NS) |
| Onoue et al44 | 133 | IRI-platinum, FOLFIRI | <60, >100 | 7.78 (1.36–44.50) | 4.27 (1.71–10.62) | – | – | – |
| Satoh et al45 | 73 | IRI | 150/2w | 9.33 (1.96–44.49) | 0.85 (0.16–4.51) | 18.18 (0.68–483.94) | – | – |
| Okuyama et al46 | 39 | FOLFIRI | 150/2w | 4.04 (0.15–108.57) | 1.93 (0.44–8.42) | – | – | – |
| Wang et al47 | 130 | FOLFIRI, IFL | 180/2w 125/1w | 0.59 (0.06–5.54) | 0.97 (0.44–2.13) | 4.47 (0.16–30.12) | 1.99 (0.77–5.13) | PFS, OS, no difference (NS) |
| Gao et al48 | 276 | FOLFIRI, XELIRI | 180/2w | 4.07 (1.50–11.04) | 2.02 (1.06–3.86) | 1.98 (0.40–9.77) | 0.90 (0.27–2.95) | RR, no difference (NS) |
| Gao et al49 | 133 | IRI-cisplatin, FOLFIRI, etc | 180/2w | 6.40 (1.30–31.60) | 3.34 (1.43–7.79) | 2.25 (0.23–21.86) | 1.13 (0.27–4.75) | – |
| Ichikawa et al50 | 1,376 | FOLFIRI, IRIS, etc | 150/2w 125/2w | 3.34 (2.19–5.10) | 1.64 (1.21–2.17) | 1.91 (NS) | 0.84 (NS) | – |
Abbreviations: CI, confidence interval; RR, response rate; PFS, progression-free survival; OS, overall survival; NS, not significant; IRI, irinotecan; FOLFIRI, 5-fluorouracil, leucovorin, irinotecan; IFL, irinotecan plus 5-fluorouracil; XELIRI, capecitabine plus irinotecan; IRIS, irinotecan plus S-1.